References
- Aiken J W, Gorman R R, Shebuski R J. Prevention of blockade of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 1979; 17: 483–5
- Dembińska-Kiec A, Gryglewska T, Zmuda A, Gryglewski R J. The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. Prostaglandins 1977; 14: 1025–34
- DeWood M A, Spores J, Notske R, Mouser L T, Burroughs R, Golden M S, Lang H T. Prevalence of total coronary occlusion during the early hours of transmural infarction. N Engl J Med 1980; 303: 897–902
- Folts J D, Crowell E B, Rowe G G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365–70
- Gryglewski R J, Bunting S, Moncada S, Flower R J, Vane J R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin x) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12: 685–91
- Higgs E A, Higgs G A, Moncada S, Vane J. Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Br J Pharmacol 1978; 63: 535–9
- Jorgensen L, Haerem J W, Chandler A B, Borchgrevink C J. The pathology of acute coronary death. Acta Anaesthesiol Scand 1968; 29(Suppl.)193–9
- MacDonald B R, Jones P BB, Russell R GG, Radford J, Martin J F. Urinary 6-oxo prostaglandin F1α in myocardial infarction. Br Med J 1983; 287: 727
- Mehta J, Mehta P. Role of blood platelets and prostaglandins in coronary artery disease. Am J Cardiol 1981; 48: 366–73
- Mehta P, Mehta J. Platelet function studies in coronary artery disease. V. Evidence for enhanced platelet microthrombus formation activity in acute myocardial infarction. Am J Cardiol 1979; 43: 757–60
- Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelets aggregation. Nature 1976; 263: 663–5
- Muller J E. Coronary artery thrombosis: Historical aspects. J Am Coll Cardiol 1983; 1: 893–6
- Prazich J A, Rapaport S I, Samples J R, Engler R. Platelet aggregate ratios—standardization of technique and test results in patients with myocardial ischemia and patients with cerebrovascular disease. Thromb Haemostas 1977; 38: 597–605
- Rohrer T F, Pfister B, Weber C, Imhof P R, Stucki P. Quantitative changes in platelet aggregation due to physiological and pathological factors and medication. Blut 1978; 36: 21–7
- Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemost 1979; 42: 803–5
- Sorkin R P, Tokarsky J M, Huber-Smith M J, Steiger J F, MaCann D S. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104: 1255–61
- Spławinska B, Furmaga W, Nieszpaur M, Ziembicki W, Kuzniar J, Dłuska Z, Rybak A, Spławiński J. Formation of prostacyclin-sensitive platelet aggregates in human whole blood in vitro. Part I. The occurrence of phenomenon in healthy male volunteers. Scand J Clin Lab Invest 1987; 47: 119–24
- Spławiński J, Gwóźdź B, Ziemibicki W, Ziajor M, Spławińska B. Anti-aggregatory activity of PGI2 in whole blood measured by platelet counter. Thromb Res 1984; 34: 93–102
- Spławiński J, Kuzniar J, Ziembicki W, Gwóźdź B, Surowiec J, Spławińska B, Szmigiel Z. Effect of PGI2 on platelet aggregates in myocardial infarction evaluate. in vitro in whole blood. The method for quantification of platelet aggregates. Biomed Biochim Acta 1984; 43: S430–3
- Wu K K, Hoak J C. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924–6